Abstract

Noroviruses (NoV) cause the great majority of epidemic nonbacterial gastroenteritis in humans. Expression of the capsid protein in recombinant systems, including insect and plant cells, yields assembly of virus-like particles (VLPs) that mimic the antigenic structure of authentic virions, and are relatively acid- and heat-stable. Norwalk virus (NV), the prototype NoV, has been studied extensively, and Norwalk virus-like particles (NVLPs) produced in insect cells and plants are immunogenic in mice and humans when delivered orally, stimulating the production of systemic and mucosal anti-NV antibodies. NVLPs are also highly immunogenic when delivered intranasally, provoking antibodies at levels similar to orally delivered VLP at much lower doses. Oral and nasal delivery of NVLPs efficiently produces antibodies at distal mucosal sites, which suggests that NVLPs could be used to deliver heterologous peptide antigens by production of genetic fusion chimeric capsid proteins. Examination of norovirus VLP surface structures and receptor binding motifs facilitates identification of potential sites for insertion of foreign peptides that will minimally affect the efficiency of VLP assembly and receptor binding. Thus, there is strong potential to use norovirus VLPs as vaccine-delivery vehicles.

Original languageEnglish (US)
Pages (from-to)299-307
Number of pages9
JournalExpert Review of Vaccines
Volume9
Issue number3
DOIs
StatePublished - 2010

Fingerprint

Virus-Like Particle Vaccines
Norwalk virus
Virion
Norovirus
Plant Cells
Capsid Proteins
Insects
Antibodies
Heterophile Antigens
Peptides
Gastroenteritis
Nose
Hot Temperature

Keywords

  • Chimeric vaccines
  • Intranasal delivery
  • Mucosal antibody
  • Mucosal immunity
  • Multivalent vaccines
  • Norovirus
  • Oral delivery
  • Vaccine platforms
  • Virus-like particle
  • VLP

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Norwalk virus-like particles as vaccines. / Herbst-Kralovetz, Melissa; Mason, Hugh; Chen, Qiang.

In: Expert Review of Vaccines, Vol. 9, No. 3, 2010, p. 299-307.

Research output: Contribution to journalArticle

Herbst-Kralovetz, Melissa ; Mason, Hugh ; Chen, Qiang. / Norwalk virus-like particles as vaccines. In: Expert Review of Vaccines. 2010 ; Vol. 9, No. 3. pp. 299-307.
@article{d283c133a64f4e9885c82733932050d6,
title = "Norwalk virus-like particles as vaccines",
abstract = "Noroviruses (NoV) cause the great majority of epidemic nonbacterial gastroenteritis in humans. Expression of the capsid protein in recombinant systems, including insect and plant cells, yields assembly of virus-like particles (VLPs) that mimic the antigenic structure of authentic virions, and are relatively acid- and heat-stable. Norwalk virus (NV), the prototype NoV, has been studied extensively, and Norwalk virus-like particles (NVLPs) produced in insect cells and plants are immunogenic in mice and humans when delivered orally, stimulating the production of systemic and mucosal anti-NV antibodies. NVLPs are also highly immunogenic when delivered intranasally, provoking antibodies at levels similar to orally delivered VLP at much lower doses. Oral and nasal delivery of NVLPs efficiently produces antibodies at distal mucosal sites, which suggests that NVLPs could be used to deliver heterologous peptide antigens by production of genetic fusion chimeric capsid proteins. Examination of norovirus VLP surface structures and receptor binding motifs facilitates identification of potential sites for insertion of foreign peptides that will minimally affect the efficiency of VLP assembly and receptor binding. Thus, there is strong potential to use norovirus VLPs as vaccine-delivery vehicles.",
keywords = "Chimeric vaccines, Intranasal delivery, Mucosal antibody, Mucosal immunity, Multivalent vaccines, Norovirus, Oral delivery, Vaccine platforms, Virus-like particle, VLP",
author = "Melissa Herbst-Kralovetz and Hugh Mason and Qiang Chen",
year = "2010",
doi = "10.1586/erv.09.163",
language = "English (US)",
volume = "9",
pages = "299--307",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Norwalk virus-like particles as vaccines

AU - Herbst-Kralovetz, Melissa

AU - Mason, Hugh

AU - Chen, Qiang

PY - 2010

Y1 - 2010

N2 - Noroviruses (NoV) cause the great majority of epidemic nonbacterial gastroenteritis in humans. Expression of the capsid protein in recombinant systems, including insect and plant cells, yields assembly of virus-like particles (VLPs) that mimic the antigenic structure of authentic virions, and are relatively acid- and heat-stable. Norwalk virus (NV), the prototype NoV, has been studied extensively, and Norwalk virus-like particles (NVLPs) produced in insect cells and plants are immunogenic in mice and humans when delivered orally, stimulating the production of systemic and mucosal anti-NV antibodies. NVLPs are also highly immunogenic when delivered intranasally, provoking antibodies at levels similar to orally delivered VLP at much lower doses. Oral and nasal delivery of NVLPs efficiently produces antibodies at distal mucosal sites, which suggests that NVLPs could be used to deliver heterologous peptide antigens by production of genetic fusion chimeric capsid proteins. Examination of norovirus VLP surface structures and receptor binding motifs facilitates identification of potential sites for insertion of foreign peptides that will minimally affect the efficiency of VLP assembly and receptor binding. Thus, there is strong potential to use norovirus VLPs as vaccine-delivery vehicles.

AB - Noroviruses (NoV) cause the great majority of epidemic nonbacterial gastroenteritis in humans. Expression of the capsid protein in recombinant systems, including insect and plant cells, yields assembly of virus-like particles (VLPs) that mimic the antigenic structure of authentic virions, and are relatively acid- and heat-stable. Norwalk virus (NV), the prototype NoV, has been studied extensively, and Norwalk virus-like particles (NVLPs) produced in insect cells and plants are immunogenic in mice and humans when delivered orally, stimulating the production of systemic and mucosal anti-NV antibodies. NVLPs are also highly immunogenic when delivered intranasally, provoking antibodies at levels similar to orally delivered VLP at much lower doses. Oral and nasal delivery of NVLPs efficiently produces antibodies at distal mucosal sites, which suggests that NVLPs could be used to deliver heterologous peptide antigens by production of genetic fusion chimeric capsid proteins. Examination of norovirus VLP surface structures and receptor binding motifs facilitates identification of potential sites for insertion of foreign peptides that will minimally affect the efficiency of VLP assembly and receptor binding. Thus, there is strong potential to use norovirus VLPs as vaccine-delivery vehicles.

KW - Chimeric vaccines

KW - Intranasal delivery

KW - Mucosal antibody

KW - Mucosal immunity

KW - Multivalent vaccines

KW - Norovirus

KW - Oral delivery

KW - Vaccine platforms

KW - Virus-like particle

KW - VLP

UR - http://www.scopus.com/inward/record.url?scp=77949451352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949451352&partnerID=8YFLogxK

U2 - 10.1586/erv.09.163

DO - 10.1586/erv.09.163

M3 - Article

C2 - 20218858

AN - SCOPUS:77949451352

VL - 9

SP - 299

EP - 307

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 3

ER -